News

GlaxoSmithKline has returned the rights to the investigational Parkinson’s disease drug Rytary to partner Impax Laboratories, citing regulatory delays.

Icon continued its run of strong quarterly results in the first three months of 2013, with operating income up by 96.0% year on year to US$23.0 million and net revenues 25.5% ahead at US$316.8 million.

Sixty percent of patients with multiple sclerosis in the UK are not receiving a disease modifying drug for their condition, despite being eligible for treatment, a new survey by the MS Society has revealed.

Drug giants Merck & Co and Pfizer have formed a new alliance to jointly develop and commercialise the latter’s ertugliflozin for the treatment of type II diabetes.

The NHS reforms in England present opportunities for GPs and other primary care staff to lead a more proactive approach to prevention and helping people remain healthy into old age – but only if they are empowered to do so, experts warn.

England’s National Institute for Health Research Clinical Research Network (NIHR CRN) has launched an online channel on BrightTALK, the webinar service for professionals and their communities.

The Ontario Institute for Cancer Research (OICR) has been chosen to set up the co-ordinating centre for a new pan-Canadian clinical-trial network in oncology.

The increasing costs of cancer drug treatments have reached unsustainably high levels and may be harming patients, a group of experts has warned.

The BMA has slammed the government for blaming the rocketing demand on accident and emergency departments in England on general practice and out of hours services.

Valeant Pharmaceuticals International’s discussions to acquire Actavis, the world’s third-largest generics drugmaker, have reportedly broken down.

Just over a week after advisors to the US Food and Drug Administration gave the thumbs-up to Breo Ellipta, GlaxoSmithKline has announced the submission of another chronic obstructive pulmonary disease drug, umeclidinium bromide, in Europe.

In its first quarter as an independent company, AbbVie has posted a strong set of financials as sales of its anti-inflammatory blockbuster Humira continued to soar.

Patients should be able to access to all their hospital, community and social service records within the next 10 years, but governance of this information must be improved, concludes a government-commissioned review of data sharing and protection. 

Novartis has expressed its dismay after the US government announced a second lawsuit against the Swiss drugmaker in four days, accusing it of paying millions of dollars in kickbacks to doctors.

The latest set of opinions from advisors to the European Medicines Agency sees five new medicines and two generics recommended for approval.